ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...
In Turkish patients from 44 centers, the R1 resection rate was higher among the EOBTC, which may reflect higher curative intent in younger patients. Recurrence-free survival (RFS) and overall survival ...
Compass Therapeutics recently reported that its Phase 2/3 COMPANION-002 trial in previously treated advanced biliary tract cancer met the primary endpoint, with tovecimig plus paclitaxel achieving ...
Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the ...
"Future guidelines panels could review these results and consider recommending the inclusion of immunotherapy with chemotherapy for the first-line treatment of advanced biliary tract cancer in the ...
Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...
The trial is testing Tovecimig in combination with Paclitaxel in patients with a rare disease affecting the bile ducts or ...
Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results